Losartan: Uses, Dosing, Side Effects, and How It Compares to Statins for Cardiometabolic Risk

What Is Losartan and How Does It Work?

Losartan blocks angiotensin II at the AT1 receptor, preventing the vasoconstriction and aldosterone secretion that angiotensin II normally drives. The result is arterial dilation, reduced fluid retention, and lower blood pressure without the bradykinin-mediated cough that affects roughly 10 to 15% of ACE inhibitor users. 1

Losartan was the first ARB approved by the FDA, receiving initial approval in 1995 under the brand name Cozaar. 2 Its active metabolite, EXP3174, is 10 to 40 times more potent than the parent compound at the AT1 receptor and accounts for most of the drug's antihypertensive effect. 3

Unlike ACE inhibitors, losartan also has a mild uricosuric effect, increasing renal uric acid excretion by roughly 25 to 30%. 4 That property makes it a preferred ARB in hypertensive patients who also carry a diagnosis of gout or hyperuricemia. Peak plasma concentration occurs 1 hour after oral dosing; the half-life of EXP3174 is 6 to 9 hours, supporting once-daily administration for most patients.

FDA-Approved Indications for Losartan

Three indications carry FDA approval: hypertension in adults and children aged 6 years and older, reduction of stroke risk in hypertensive patients with left ventricular hypertrophy (LVH), and slowing the progression of diabetic nephropathy in patients with type 2 diabetes and proteinuria. 5

Hypertension. In the LIFE trial (N=9,193), losartan reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol (RR 0.87 to 95% CI 0.77, 0.98) over a mean follow-up of 4.8 years, with stroke reduction of 25% driving most of the benefit. 6 The blood-pressure reduction between arms was nearly identical, suggesting benefits beyond blood pressure lowering.

Diabetic nephropathy. The RENAAL trial (N=1,513) demonstrated that losartan 50 to 100 mg daily reduced the risk of doubling serum creatinine by 25% and the risk of end-stage renal disease by 28% compared with placebo in patients with type 2 diabetes and nephropathy. 7 Both groups received conventional antihypertensive therapy, isolating the ARB-specific renoprotective effect.

Stroke prevention in LVH. In LIFE, the pre-specified subgroup with LVH by electrocardiogram showed a 25% relative risk reduction in stroke with losartan versus atenolol (P<0.001). 6 The FDA subsequently approved losartan specifically for this indication.

Dosing and Titration

Standard starting dose is 50 mg once daily. 5 Patients who are volume-depleted, on dialysis, or have hepatic impairment should start at 25 mg once daily to reduce first-dose hypotension risk. The dose may be titrated to 100 mg once daily after 4 to 8 weeks if blood pressure remains above target.

For diabetic nephropathy, the RENAAL protocol began patients at 50 mg daily and titrated to 100 mg daily at week 4 if blood pressure was not controlled. 7 Losartan may be combined with a low-dose thiazide diuretic such as hydrochlorothiazide 12.5 to 25 mg when monotherapy is insufficient. The 2017 ACC/AHA hypertension guideline defines the blood pressure target for most adults at <130/80 mmHg. 8

Pediatric dosing for children aged 6 to 16 years starts at approximately 0.7 mg/kg once daily (maximum 50 mg), with titration guided by response. Losartan is not recommended in children with a glomerular filtration rate <30 mL/min/1.73 m² due to limited pharmacokinetic data in that population.

Side Effects and Safety Profile

Losartan is generally well tolerated. The most common adverse effect reported in clinical trials is dizziness, occurring in approximately 3 to 7% of patients. 5

Hyperkalemia. Blocking aldosterone secretion reduces urinary potassium excretion. Potassium levels should be checked 1 to 4 weeks after initiation, particularly in patients with chronic kidney disease or those already taking potassium-sparing diuretics or trimethoprim. 9

Renal function changes. A rise in serum creatinine of up to 30% after starting losartan is considered acceptable and does not require drug discontinuation; it reflects reduced intraglomerular pressure rather than true renal injury. 10 Increases beyond 30 to 35% warrant investigation.

Angioedema. Rare but possible. The incidence is approximately 10-fold lower than with ACE inhibitors. 11 Patients with a prior history of ACE inhibitor-induced angioedema should use losartan only with caution and appropriate monitoring.

No dry cough. Because losartan does not raise bradykinin levels, the chronic dry cough that causes roughly 10 to 15% of ACE inhibitor users to discontinue therapy does not occur with losartan. 1 This makes it the preferred agent when ACE inhibitor cough is a documented problem.

Pregnancy. Losartan is absolutely contraindicated in all trimesters. Fetal exposure during the second and third trimesters causes fetal renal dysplasia, oligohydramnios, and skull hypoplasia. 5 Women of reproductive age require counseling and reliable contraception.

Drug Interactions

Losartan is metabolized primarily by CYP2C9, with minor CYP3A4 involvement. 12 Inhibitors of CYP2C9 such as fluconazole can raise losartan exposure approximately 50%, while strong inducers such as rifampin can reduce active metabolite levels by up to 40%.

NSAIDs reduce the antihypertensive effect of ARBs and may acutely impair renal function when combined. 13 Regular NSAID use should prompt blood pressure reassessment within 2 to 4 weeks.

Dual renin-angiotensin-aldosterone system blockade with an ACE inhibitor plus an ARB increases the risk of hypotension, hyperkalemia, and renal impairment without additional cardiovascular benefit. The FDA added a black-box warning against this combination after the ONTARGET trial (N=25,620) showed harm without benefit from combined ramipril plus telmisartan. 14 Aliskiren combined with losartan is also contraindicated in patients with diabetes or a GFR <60 mL/min. 5

Lithium. ARBs decrease lithium clearance and can raise lithium levels into the toxic range. Serum lithium should be monitored closely when losartan is started or the dose is changed. 15

Losartan and Statins: Building a Complete Cardiometabolic Regimen

Most patients with hypertension also carry dyslipidemia. Losartan addresses blood pressure; statins address LDL-C. These drug classes have no pharmacokinetic interaction, and prescribing them together is standard practice in cardiometabolic medicine. 16

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "Statin therapy is recommended for adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL and an estimated 10-year CVD risk of 7.5% or higher." 16 A hypertensive patient already on losartan who meets that threshold should receive a statin without delay.

Atorvastatin (Lipitor)

Atorvastatin is a high-intensity statin that reduces LDL-C by 40 to 60% depending on dose. 17 The ASCOT-LLA trial (N=10,305) randomized hypertensive patients with at least three additional cardiovascular risk factors to atorvastatin 10 mg or placebo; atorvastatin reduced fatal and non-fatal myocardial infarction by 36% (HR 0.64, P<0.0001) and fatal/non-fatal stroke by 27% (HR 0.73, P=0.024) at a median 3.3 years. 18 Because many participants in ASCOT-LLA were on antihypertensive therapy including ARBs, this trial is directly relevant to the losartan-plus-atorvastatin combination seen in clinical practice.

Standard dosing: 10 to 80 mg once daily, taken at any time of day. Atorvastatin is the most prescribed statin in the United States and carries the longest post-marketing safety record among high-intensity agents. 19

Rosuvastatin (Crestor)

Rosuvastatin is the most potent statin by milligram: 20 mg reduces LDL-C by approximately 52 to 55%, and 40 mg by 55 to 63%. 20 JUPITER (N=17,802) enrolled adults with LDL-C <130 mg/dL but elevated high-sensitivity CRP and showed that rosuvastatin 20 mg daily reduced the composite of major cardiovascular events by 44% (HR 0.56, P<0.00001) versus placebo after a median 1.9 years. 21

Rosuvastatin is not metabolized by CYP3A4, making it less prone to interactions with CYP3A4 inhibitors compared to atorvastatin. 22 Standard dosing: 5 to 40 mg once daily. The 40 mg dose requires specific documentation of cardiovascular risk given the incremental myopathy risk at higher exposures.

Simvastatin (Zocor)

Simvastatin was the backbone of cardiovascular prevention trials for two decades. The Heart Protection Study (N=20,536) showed simvastatin 40 mg daily reduced major vascular events by 24% (P<0.0001) across a broad population including patients with prior stroke, PAD, and diabetes, regardless of baseline LDL-C. 23

Simvastatin 80 mg is no longer recommended for new patients due to a 1-in-52 risk of myopathy at that dose identified in the SEARCH trial (N=12,064). 24 The FDA issued a safety communication restricting simvastatin 80 mg to patients already stable on that dose for 12 months or more. 25 The maximum recommended starting dose is 40 mg once daily, taken in the evening because hepatic cholesterol synthesis peaks overnight.

Simvastatin is heavily metabolized by CYP3A4. Concurrent use of strong CYP3A4 inhibitors such as clarithromycin, itraconazole, or large quantities of grapefruit juice raises simvastatin plasma concentrations substantially and increases myopathy risk. 25 Losartan does not inhibit CYP3A4 and does not interact with simvastatin pharmacokinetically.

Ezetimibe (Zetia)

Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, reducing cholesterol absorption by approximately 50% and lowering LDL-C by 18 to 25% as monotherapy. 26 Added to a statin, ezetimibe provides an additional 18 to 23% LDL-C reduction beyond the statin alone. 27

The IMPROVE-IT trial (N=18,144) compared simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo in patients after acute coronary syndrome. The combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the statin-only arm and reduced the 7-year composite cardiovascular endpoint by 6.4% absolute risk (P=0.016). 27 This trial confirmed that LDL-C lowering below 70 mg/dL provides incremental benefit, a principle now embedded in the 2022 ACC Expert Consensus on Non-Statin Therapies. 28

Ezetimibe is well suited for patients who cannot tolerate maximum statin doses and for those who remain above LDL-C targets despite high-intensity statin therapy. It has no relevant interaction with losartan. 26

Choosing Between Statins: A Practical Framework

Selecting the right statin alongside losartan depends on four variables: required LDL-C reduction, concomitant medications, tolerability history, and cost.

Patients who need 40 to 60% LDL-C reduction and have no relevant CYP3A4 drug interactions may do well with atorvastatin 20 to 40 mg. Those who need greater than 50% reduction and prefer to avoid CYP3A4-related interactions may benefit from rosuvastatin 20 mg. Simvastatin 40 mg remains a cost-effective moderate-intensity option where CYP3A4 inhibitor co-administration is absent. When any statin does not achieve the target or causes myalgia at therapeutic doses, adding ezetimibe 10 mg daily is the recommended next step before escalating to a PCSK9 inhibitor. 28

The 2019 ACC/AHA guideline specifies: "For patients with clinical ASCVD, high-intensity statin therapy or maximally tolerated statin therapy is recommended to reduce LDL-C levels by 50% or more." 16 Losartan is the blood pressure agent most commonly paired with these regimens because it adds renal protection in diabetic patients and carries a favorable tolerability profile, particularly absence of cough.

Monitoring Parameters After Starting Losartan

Serum creatinine, blood urea nitrogen, and potassium should be checked at baseline and again 1 to 4 weeks after any dose change. 9 Blood pressure should be measured at each visit, targeting below 130/80 mmHg in most adults per ACC/AHA 2017 criteria. 8

If losartan is prescribed alongside a statin, a fasting lipid panel is appropriate at baseline and 6 to 12 weeks after statin initiation or dose change to verify LDL-C response. 16 Liver function tests are no longer routinely recommended for statin monitoring unless symptoms of hepatotoxicity arise, per a 2012 FDA label update removing routine ALT monitoring requirements from statin labeling. 29

Creatine kinase testing is indicated if a patient reports muscle pain, weakness, or brown urine, regardless of which statin is prescribed. 30 Statin-associated muscle symptoms occur in 5 to 10% of patients in observational studies, though placebo-controlled data suggest a lower rate. 30

Special Populations

Patients with diabetes. Losartan's renoprotective benefit in type 2 diabetic nephropathy is well established from RENAAL. 7 The ADA Standards of Care in Diabetes recommend ARB or ACE inhibitor therapy for patients with diabetes who have hypertension and urine albumin-to-creatinine ratio above 300 mg/g or eGFR 25 to 60 mL/min. 31 Statin therapy is also recommended for virtually all adults with type 2 diabetes aged 40 to 75 years under the same guidelines, making the losartan-plus-statin combination nearly universal in this population.

Elderly patients. Blood pressure targets in patients aged 65 and older remain <130 mmHg systolic when tolerated, per the 2017 ACC/AHA guideline, provided orthostatic hypotension is absent. 8 Losartan's once-daily dosing and low incidence of orthostatic hypotension make it practical in older adults. The starting dose of 25 to 50 mg is appropriate, with slower titration than in younger patients.

Chronic kidney disease without diabetes. Kidney Disease Improving Global Outcomes (KDIGO) 2021 guidelines recommend ARB or ACE inhibitor therapy for patients with CKD and hypertension regardless of diabetic status when proteinuria is present (urine albumin-to-creatinine ratio above 300 mg/g). 32 Losartan satisfies this recommendation and also reduces cardiovascular risk through blood pressure reduction.

Women considering pregnancy. Losartan must be stopped before conception or as soon as pregnancy is confirmed. Women of childbearing potential should receive explicit counseling at every visit. 5 A switch to methyldopa, labetalol, or nifedipine is appropriate during pregnancy when antihypertensive therapy is needed.

Cost and Access

Losartan is available as a generic at virtually every US pharmacy. Typical cash-pay cost is $10, 15 per month for a 30-day supply of 50 mg or 100 mg tablets. 33 Atorvastatin, rosuvastatin, simvastatin, and ezetimibe are also available generically. A patient prescribed losartan 50 mg plus atorvastatin 20 mg plus ezetimibe 10 mg could pay under $45 per month at cash prices. The combination tablet amlodipine/atorvastatin (Caduet) exists for patients who need both calcium channel blocker and statin, but no FDA-approved losartan/statin fixed-dose combination is currently marketed in the United States.